Evidence map›Paper›PMID 42269969›Full record

Observational studyThe American journal of clinical nutrition2026

Circulating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study.

Aleix Sala-Vila, Catarina Tristão-Pereira, Iolanda Lázaro, Mehrnaz Shekari, Alberto Fernández-Pena, Jennifer Monereo-Sánchez, Ines Garcia-Lunar, Cristina Perez-Herreras, Maria Angeles Moro, Ana Garcia-Alvarez and 5 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in The American journal of clinical nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01410318 (Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01410318 active not recruitingnot on this map

Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors

TypeobservationalSponsorFundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIRan2010 to 2030Enrolled4,184ConditionsAtherosclerosis
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aleix Sala-VilaGroup of Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute, Barcelona, Spain; Fatty Acid Research Institute (FARI), Sioux Falls, SD, USA; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
Catarina Tristão-PereiraCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Iolanda LázaroGroup of Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute, Barcelona, Spain; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
Mehrnaz ShekariGroup of Cardiovascular Risk and Nutrition, Hospital del Mar Research Institute, Barcelona, Spain; Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Alberto Fernández-PenaCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Jennifer Monereo-SánchezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Ines Garcia-LunarCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Cardiology Department, University Hospital La Moraleja, Madrid, Spain; Centro de Investigación Biomédica en Red de de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Cristina Perez-HerrerasSantander Bank, Madrid, Spain.
Maria Angeles MoroCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Ana Garcia-AlvarezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Centro de Investigación Biomédica en Red de de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Javier Sanchez-GonzalezPhilips Healthcare Iberia, Madrid, Spain.
Juan Domingo GispertCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
Borja IbanezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Centro de Investigación Biomédica en Red de de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain; Health Research Institute, Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Valentin FusterCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: vfuster@cnic.es.
Marta Cortes-CanteliCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Centro de Neurociencias Cajal-Consejo Superior de Investigaciones Científicas (CNC-CSIC), Madrid, Spain. Electronic address: mcortes@cnic.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExcess energy intake upregulates de novo lipogenesis (DNL). Circulating palmitoleic acid (POA) is an objective DNL biomarker associated with higher cardiovascular risk, which has been linked to cerebral hypometabolism. Whether POA also relates to altered cerebral glucose metabolism in midlife remains unknown.

objectivesThis study aimed to examine cross-sectional and longitudinal associations between circulating POA (predictor) and cerebral glucose hypometabolism (outcome), a neuroimaging marker linked to increased risk of subsequent cognitive decline.

methodsWe studied 461 middle-aged [median age, 51 (47-54) y] individuals with subclinical atherosclerosis from the Progression of Early Subclinical Atherosclerosis (PESA) study, a longitudinal observational cohort of asymptomatic individuals (NCT01410318). Red blood cell (RBC) POA was quantified by gas chromatography in blood samples collected at 2 visits of PESA participants who had undergone longitudinal cerebral

resultsCross-sectionally, higher RBC POA was associated with widespread lower FDG uptake across the brain [β = -0.119 (95% confidence interval: -0.206, -0.032), P = 0.007], even after adjusting for cardiovascular risk. Longitudinally, participants with sustained high RBC POA exhibited a 65% greater decline in cerebral FDG uptake compared with those with sustained low POA [β = -0.403 (-0.744, -0.063), P = 0.021], particularly in frontal and parietal regions. RBC POA proportions were higher among individuals adhering to the predefined "Social-Business" dietary pattern and were significantly associated with increased alcohol intake. Furthermore, the association between alcohol intake and subsequent precuneus hypometabolism was partially mediated by RBC POA proportions.

conclusionsRBC POA, a marker of DNL, is associated with cerebral glucose hypometabolism, supporting that healthy dietary habits in midlife are key to preserving brain health. This trial was registered at clinicaltrials.gov as NCT01410318.

Indexed as

AtherosclerosisBrainFatty Acids, MonounsaturatedGlucoseBiomarkersCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedPositron-Emission TomographyProspective StudiesBiomarkersFatty Acids, MonounsaturatedGlucosepalmitoleic acidbiomarkersbrain healthdietenergy metabolismneuroimaging

Identifiers

PMID42269969
PMCPMC13494094

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.